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Background: Despite 10 to% of persons living with HIV in sub-Saharan Africa having clinical depression, and the
consequences of depression for key public health outcomes (HIV treatment adherence and condom use), depression
treatment is rarely integrated into HIV care programs. Task-shifting, protocolized approaches to depression care have
been used to overcome severe shortages of mental health specialists in developing countries, but not in sub-Saharan
Africa and not with HIV clients. The aims of this trial are to evaluate the implementation outcomes and cost-effectiveness
of a task-shifting, protocolized model of antidepressant care for HIV clinics in Uganda.
Methods/Design: INDEPTH-Uganda is a cluster randomized controlled trial that compares two task-shifting models of
depression care - a protocolized model versus a model that relies on the clinical acumen of trained providers to provide
depression care in ten public health HIV clinics in Uganda. In addition to data abstracted from routine data collection
mechanisms and supervision logs, survey data will be collected from patient and provider longitudinal cohorts; at each
site, a random sample of 150 medically stable patients who are depressed according to the PHQ-2 screening will be
followed for 12 months, and providers involved in depression care implementation will be followed over 24 months.
These data will be used to assess whether the two models differ on implementation outcomes (proportion screened,
diagnosed, treated; provider fidelity to model of care), provider adoption of treatment care knowledge and practices,
and depression alleviation. A cost-effectiveness analysis will be conducted to compare the relative use of resources by
each model.
Discussion: If effective and resource-efficient, the task-shifting, protocolized model will provide an approach to building
the capacity for sustainable integration of depression treatment in HIV care settings across sub-Saharan Africa
and improving key public health outcomes.
Trial registration: INDEPTH-Uganda has been registered with the National Institutes of Health sponsored
clinical trials registry (3 February 2013) and has been assigned the identifier NCT02056106.
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Over 25 million people living with HIV (PLWHIV) res-
ide in sub-Saharan Africa (SSA), including over 1 million
in Uganda [1]. Scaled-up access to HIV antiretroviral
therapy (ART) has led to nearly 10 million in SSA and
just under 300,000 Ugandans receiving treatment by
the end of 2012 [1], resulting in dramatic declines in
mortality [2,3] and HIV becoming a chronic, manageable* Correspondence: gwagner@rand.org
1RAND Corporation, Santa Monica, CA, USA
Full list of author information is available at the end of the article
© 2014 Wagner et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.disease [4]. ART also contributes to HIV prevention by
reducing infectiousness [5,6], and being associated with
increased condom use [7,8]. However, depression has
emerged as a major threat to the success and benefits of
ART, as it impedes ART adherence [9-11] and condom
use [12-14], and has been associated with a greater like-
lihood of mortality [15-17] and worse immunologic and
virologic response to treatment [18-21]. Clinical depres-
sion, as diagnosed by structured clinical interviews, gen-
erally ranges from 10 to 20% among PLWHIV in SSA
[22-24], while an additional 20 to 30% have elevatedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tions are effective in treating depression in PLWHIV
[28], including antidepressants [29,30], and depression
treatment improves ART use, adherence and outcomes
[31-34]. Yet despite the prevalence of depression and its
consequences for the fight against HIV, depression
treatment is rarely integrated into HIV care programs
in SSA [35].
A severe shortage of mental health professionals is a
key barrier to depression care in Uganda and the larger
region [36]. There are just over thirty psychiatrists in
Uganda or one for every one million citizens, and most
are in or near the capital city Kampala. Given the lack of
psychiatrists, it is generally left to primary care providers
to diagnose and treat depression. However, whether it is
due to lack of psychiatric training, lack of appreciation
of the value of mental health care, or lack of time and
resources, providers have shown a reluctance to engage
in mental health treatment in Uganda, even though anti-
depressants are on the national formulary and free of
charge. Perhaps in part because depressed patients often
present first with somatic symptoms, providers prefer to
first rule out possible physical and medical causes rather
than evaluating mental illness [36]. Often it is only when
mental illness is so advanced that it is causing obvious
disruption and dysfunction, do providers consider men-
tal illness and then attempt to refer out to psychiatric
specialists [36]. Even if depression care training were
provided and primary care providers had a greater ap-
preciation for mental health care, most HIV clinics in
Uganda have only 1 clinical or medical officer for seeing
50 to 100 patients daily; so the concern is that many de-
pressed patients would still go undetected, and bottle-
necks of patients waiting for providers would worsen.
Understanding how to effectively implement evidence-
based treatment in HIV settings, where need is high and
mental health capacity is virtually non-existent is essen-
tial. With the emphasis on developing feasible, sustain-
able models of health care delivery in resource-poor
settings, task-shifting models have presented a solution
to scarce highly trained health professionals [37,38].
Task-shifting involves training lower cadres to take on
many of the duties traditionally performed by more
highly trained providers who are less available. Task-
shifting, nurse-driven care has been shown to result in
equivalent levels of quality of care in the context of HIV
care and ART scale-up in SSA [39,40]. As a result, task-
shifting is an approach widely used to facilitate HIV care in
Uganda, with nurses often assuming the role of primary
care provider, and a clinical or medical officer being present
for oversight and to handle more complicated cases. This
task-shifting approach has not been adapted for manage-
ment of depression treatment for HIV patients, but ‘collab-
orative care’ models of depression treatment have beenimplemented with non-HIV patients in the US [41-44] as
well as resource constrained settings [45-47]. These models
use a team-based approach, typically consisting of a depres-
sion care manager (often a nurse), primary care provider
and supervising psychiatric specialist in medical settings,
and a structured, algorithm-based protocol that enables the
care manager to take over many of the responsibilities of
antidepressant therapy management. Controlled studies
have demonstrated the effectiveness of collaborative care
models [48-51]; furthermore, algorithm-based, protocol-
driven care has been associated with better quality of care
and treatment outcomes [43,46,48,49], as the structured ap-
proach results in greater likelihood of adequate treatment
dosage and duration [52].
INDEPTH (INtegration of DEPression Treatment in
HIV care)-Uganda is a cluster randomized trial that at-
tempts to identify an effective, resource-efficient model
for integrating depression treatment into HIV care in
low resources settings such as Uganda. In the HIV
clinics of ten health care facilities, the trial is comparing
two active task-shifting implementation models of de-
pression care: a protocolized model in which care is pro-
vided largely by trained nurses who act as depression
care managers, and a model that relies on the clinical
acumen of trained primary care providers (most, but not
all, of whom are also nurses). An alternative approach to
the use of a structured protocol to guide depression care
by non-mental health professionals, the clinical acumen
model (like the protocolized model) takes an active ap-
proach to depression care by integrating a brief routine
depression screening process for all patients at each
clinic visit, but what the primary care provider does with
this screening information is left to their discretion as
opposed to following a structured protocol. So, both of
these models are active task-shifting models of depres-
sion care, as the clinical acumen model goes beyond
current usual care, which relies solely on primary care
provider to assess and treat, or refer to external special-
ists - which has resulted in depression being severely
under-diagnosed and treated.
According to the RE-AIM (Reach, Effectiveness, Adop-
tion, Implementation, Maintenance) implementation
framework, to have an impact on health at the popula-
tion level, an intervention must be adopted by providers,
reach a large proportion of the patient population, be
implemented with fidelity, effectively improve outcomes,
and be maintained post study [53,54]. Accordingly, the
objectives of INDEPTH-Uganda are to compare the two
task-shifting models on (1) reach (screening and follow-
up rates), adoption (treatment uptake), fidelity (quality
of depression care implementation by the providers),
and effectiveness (alleviation of depression symptoms)
implementation parameters, and (2) cost-effectiveness. A
secondary objective is to assess the impact of depression
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(ART adherence, condom use) outcomes. Our hypothesis
is that the protocolized model will result in better imple-
mentation of depression care, better overall alleviation of
depression, and better cost-effectiveness, compared to
clinical acumen. If effective and resource-efficient, the
protocolized model will provide an approach to building
the capacity for sustainable provision of depression
treatment across SSA and improving key public health
outcomes of HIV care.
Methods
Study design
INDEPTH-Uganda is a comparative trial that compares
two active task-shifting implementation models for inte-
grating antidepressant treatment into HIV care within
ten health care facilities in Uganda. Using a cluster
randomization, five clinics are assigned to implement a
protocolized model, and five others rely on the clinical
acumen of trained providers. One of the investigators
(EO) will generate a random list of numbers using com-
puter software which will be printed on opaque pieces of
paper that will be folded and drawn by clinic representa-
tives in a meeting in which representatives from all
clinics are present. To ensure the two study arms are
balanced on size of clientele (small clinics serve 300 to
1,000 clients, while larger clinics serve 1,500 to 3,000 cli-
ents), which could influence depression care processes,
randomization will be conducted within pairs of clinics
that were matched on this variable. The models will be
implemented over 24 months starting in spring 2013. To
evaluate the models, data will be collected from docu-
mentation mechanisms integrated into routine care, and
from random samples of 150 patients enrolled at each
site (total n = 1,500) that screen positive for possible
depression and are followed for 12 months. We will com-
pare the two models on uptake of antidepressant treatment,
and change in depression (treatment response), as well as
other quality of care and implementation outcomes as out-
lined by the RE-AIM implementation framework. This co-
hort will also be used to examine the relationship between
change in depression and key economic and public health
outcomes (for example, work status, condom use, HIV
treatment adherence). A cohort of providers from each site
will also be enrolled and followed over the 24-month im-
plementation to examine change in knowledge, attitudes
and practices regarding depression care and perceived im-
pact of the implementation on clients, providers and clinic
operations. Patient and provider survey data will be col-
lected by trained research coordinators who will not be
blinded to the treatment condition, nor will the patient par-
ticipants. All patient and provider participants will provide
written informed consent prior to enrollment. Lastly, a
cost-effectiveness analysis will be conducted to examine therelative cost and resources needed to implement each
model. The study protocol has been approved by Institu-
tional Review Boards at RAND Corporation (protocol #
2012-0115), Mildmay Uganda, and the Uganda National
Council for Science and Technology.
The success of the study depends on engagement with,
and commitment from, the leadership and staff of the
health care facilities, district level administration, and
the Ministry of Health. This is critical to the program
being feasible, responsive to the local context of the
clinics, and thus also sustainable once the project has
ended. A kick-off meeting with all key stakeholders will
be held to review the care models and elicit feedback on
logistical implementation, as well as to secure buy-in
and partnership in the study. A Core Planning Group,
with representatives from all cadres involved in the
model (expert clients, nurses, clinical/medical officers),
will be convened on a quarterly basis, as well as consult-
ation with district health administration leadership, and
Dr. Sheila Ndyanabangi (mental health point person in
the Ministry of Health). With the goal of establishing a
model of depression care that is sustainable and scalable,
the focus of this group is to engage in an iterative process
for planning and coordinating implementation, trouble-
shooting any challenges that arise, and deciding on neces-
sary modifications or refinements to the models.
Study setting
The study is being conducted in collaboration with
Mildmay Uganda, a non-government organization that
provides holistic outpatient HIV care at its own clinics,
trains health care workers throughout Uganda and the
region, and provides technical assistance in HIV care to
health care facilities across Uganda. Of the ten health
care facilities participating in the study, eight are run by
the Ministry of Health and two are private, faith-based,
not-for-profit health care facilities; two are district hospi-
tals and the others are designated as health centre III or
IV facilities by the Uganda Ministry of Health, and are
located in the districts of Mpigi, Mityana, Luweero, and
Wakiso. Each facility is a hospital that operates an HIV
clinic on specific designated days of the week, and it is
in these clinics that depression care is being integrated
as part of this study. The 6 larger clinics operate 2 to
3 days per week and generally have 1 clinical or medical
officer and 3 to 5 nurses to provide primary HIV care to
a clientele ranging from 1,500 to 3,000 clients and 80 to
120 patients are seen each clinic day. The 4 smaller
clinics operate 1 day per week and are manned by 1 clin-
ical or medical officer and 2 to 3 nurses; client base
ranges from 350 to 1,000, with 40 to 60 patients seen
each day.
Consistent with task-shifting approaches becoming in-
creasingly common in the context of ART scale-up across
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viders (along with the clinical/medical officers), and manage
the prescription and monitoring of ART and other com-
mon HIV medications; more complex conditions or com-
plications that arise are typically managed by the clinical/
medical officer. All clinics have expert clients (volunteer ex-
perienced HIV clients who display exemplary HIV care ad-
herence and are trained to provide peer support and assist
in lower level tasks) and village health team (VHT) workers
(community lay volunteers) who volunteer to take on tasks
such as triage assessments, filing and retrieving charts, and
keeping the clinic clean. No psychiatric or depression care
services were being provided at these clinics prior to the
study; clients who developed significant psychiatric symp-
toms are referred to the nearest district or regional hospital
for care.
Task-shifting depression care models
Protocolized model
Drawing from collaborative care models of depression
treatment such as Partners in Care, MANAS and
STAR*D [42,44,46,47], the protocolized model imple-
ments an algorithm-based, nurse-driven approach to ad-
ministering depression diagnosis and antidepressant
therapy. While other collaborative care models incorpor-
ate psychotherapy and reserve antidepressants for severe
depression, our model focuses solely on the use of anti-
depressants. We believe that use of medication requires
relatively less trained resources and personnel time than
would be needed to add a form of psychotherapy, result-
ing in a more reliable and scalable treatment for re-
source constrained settings. The components of the
protocolized model are outlined below and summarized
(in comparison with the clinical acumen model) in
Table 1.
Routine depression screening
All adult clinic patients will be screened for depression
at each clinic visit using the first two items of the Patient
Health Questionnaire (PHQ-2) [55], administered at the
triage station (along with measurements of body weight,
blood pressure, pulse and elicitation of presenting health
problems) by expert clients or VHT workers. The PHQ-
2 assesses depressed mood and loss of interest; patients
who screen positive for depression (3+ scores; range: 0
to 6) will be referred to the nurse in the protocolized
model for further depression evaluation if medically
stable; in the clinical acumen model, PHQ-2 data are
relayed to the primary care provider. Medical stability is
defined as not about to start (or recently started) ART
or treatment for an acute opportunistic infection (see
Figure 1). Further evaluation is deferred for medically
unstable patients until their condition and treatment is
stable as mood may improve once they are medicallystable, and starting antidepressants simultaneously with
other medical treatments would complicate side effect
and response evaluation. However, depressed patients
who are medically unstable will be evaluated for suicide
risk and the need for immediate treatment.
Depression diagnosis
Further evaluation of patients who screen positive for
depression and are medically stable will be conducted
using the full nine-item Patient Health Questionnaire
(PHQ-9) [55]. Patients who score greater than 9 on the
PHQ-9 (range: 0 to 27), which has been shown to cor-
respond highly with major depression (88% sensitivity
and specificity) as determined by a diagnostic interview
[55], will be further assessed using the criteria for major
depression on the Mini Neuropsychiatric Interview
(MINI; five symptoms scored as three on the PHQ-9, at
least one of which is depressed mood or loss of interest)
[56]. Providers are trained to further assess antidepres-
sant eligibility using the MINI screening items for bipo-
lar disorder, psychosis and substance abuse, as well as
medical contraindications (for example, pregnancy or
breast feeding, seizure disorder); for patients with these
conditions, the supervising psychiatrist will be consulted
to determine appropriate treatment.
Prescription of antidepressants
If eligibility for antidepressant therapy is confirmed, the
provider (nurse in the protocolized model and primary
care provider in the clinical acumen model) will educate
the patient about depression as a disease, and anti-
depressant treatment, including: prognosis, the goal of
symptom remission, that treatment often takes two to
three weeks to have an effect, and that side effects are
generally minor and temporary. Helping the patient to
understand the treatment is intended to encourage ad-
herence to treatment. The patient will then receive a
prescription and supply of either fluoxetine or imipra-
mine prior to departing the clinic, which the provider
will select based on the patient’s presenting symptoms
and psychiatric history; fluoxetine will be prescribed un-
less the patient presents with insomnia, sexual dysfunc-
tion or history of bipolar disorder. Fluoxetine has been
shown to have some drug interactions with HIV prote-
ase inhibitors [57], but protease inhibitors are rarely
used in Uganda.
Monitoring of treatment response and side effects
After treatment prescription, the patient will return to
see the prescribing provider two weeks later for moni-
toring of side effects, treatment response and any need
for change in dosage or medication. The visit schedule
will then become monthly until the patient has been in
remission (defined as PHQ-9 < 5 and tolerating any side
Table 1 Components of the protocolized and clinical acumen depression care models
Protocolized model Clinical acumen
Training •One day training for all involved cadre •One day training for all involved cadre
•On-site training and oversight by study staff during first four weeks of
implementation
•On-site training and oversight by study staff during first
four weeks of implementation
•Periodic training schedule to train new staff that emerge (typically site
specific)





•All adults screened with 2-item PHQ-2 at each clinic visit •All adults screened with 2-item PHQ-2 at each clinic visit
•Performed at triage station (Expert-clients/VHTs) •Performed at triage station (Expert-clients/VHTs)
•PHQ-2 > 2 signifies depression, continue to Step 2 •PHQ-2 > 2 signifies depression, continue to Step 2
Documentation: Clinic’s triage book Documentation: Clinic’s triage book
STEP 2:
Diagnosis
•Is patient’s treatment status (either ART or OI treatment) in flux (about
to start or newly started)? (Nurse)YES = not medically stable, so wait and
monitorNO =medically stable, administer PHQ-9
•PHQ-2 score is relayed to prescribing clinician
•Prescribing clinician uses their judgment to determine
whether to further evaluate depression, rather than a
protocol
•Administer PHQ-9 (Nurse) •However, prescribing clinicians are trained to follow-up
positive PHQ-2 screens with:
•PHQ-9 > 9 signifies clinical depression 1) Assessment of medical stability
•Consider MINI criteria to determine diagnosis 2) PHQ-9
•If meets criteria for diagnosis, continue to Step 3 3) Consider MINI criteria




•Provide psychoeducation to client about depression and what to
expect from antidepressant treatment (Nurse)
•Provide psychoeducation to client about depression and
what to expect from antidepressant treatment (Prescribing
Clinician)
•Select most appropriate antidepressant •Select most appropriate antidepressant
•Prescribe antidepressant •Prescribe antidepressant
•Schedule follow-up visit two weeks later •Schedule follow-up visit two weeks later




•Follow-up at Week 2 and then monthly until responding, then
scheduled with routine clinic visit
•Follow-up at Week 2 and then monthly until responding,
then scheduled with routine clinic visit
•At each follow-up, assess side effects, symptoms and need for medica-
tion or dose change (Nurse)
•At each follow-up, assess side effects, symptoms and need
for medication or dose change (Prescribing Clinician)
Documentation: Depression Treatment Registry Documentation: Depression Treatment Registry
STEP 5: Stop
treatment
•Stop treatment once patient responding for six months (unless patient
has had 2+ prior episodes, then continue for two years)
•Stop treatment once patient responding for six months
(unless patient has had 2+ prior episodes, then continue
for two years)
•Taper down dosage using dosing protocol •Taper down dosage using dosing protocol
Documentation: Depression Treatment Registry Documentation: Depression Treatment Registry
Supervision •Psychiatrist assigned to each clinic •Psychiatrist assigned to each clinic
•Supervision visits are done monthly •Supervision visits are done monthly
Legend: ART, antiretroviral therapy; OI, opportunistic infection; MINI, Mini Neuropsychiatric Interview; PHQ, Patient Health Questionnaire; VHT, village health team.
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will be modified to match the patient’s HIV care visit
schedule (typically every two to three months), but no
less than every three months; if the patient experiences a
relapse, visits will return to monthly until in remission.
At each visit, the provider will assess depressive symp-
toms (using the PHQ-9), presence of side effects and
strategies for managing such symptoms, as well as
enquire about medication adherence. Psychoeducation
regarding depression treatment will continue and beemphasized as needed. A Depression Treatment Registry
will been instituted at each site in which the above listed
parameters are recorded for each visit, as well as medi-
cation and dosage prescribed. These data will be
reviewed during supervision and used for reference in
future follow-up visits, as well as for tracking fidelity to
the treatment protocol.
Starting daily dose is 20 mg for fluoxetine and 50 mg
for imipramine; imipramine will increase to 75 mg after
one week. Patients remain on this low dose until their
Figure 1 Depression and treatment eligibility assessment protocol. PHQ= Patient Health Questionnaire. OI = opportunistic infections. Rx = treatment.
Dx = diagnosis. ART = antiretroviral therapy.
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termination of the need for a change in dose or medica-
tion will be considered based on measures of depressive
symptoms and side effects (see Figure 2). For patients
tolerating any side effects: dose will remain the same if
they are fully responsive to treatment; for partial re-
sponders, the provider will decide whether to maintain
the dose or increase by one increment (add 20 mg of flu-
oxetine or 25 mg of imipramine); nonresponders will
have their dose increased by one increment. For patients
not tolerating side effects: if a full or partial response to
treatment, the current dose may be maintained and side
effects addressed (with pharmacologic or other types ofFigure 2 Algorithm for dose or medication changes. PHQ = Patient Heastrategies) or the provider may reduce the dose or
change the antidepressant; for nonresponders, the anti-
depressant will be changed.
This algorithm-based treatment decision process is re-
peated at each monthly visit until the patient is fully
responding and in remission - the medication dose will
then remain the same (unless subsequent changes are
needed due to side effects or relapse). Maximum dose is
80 mg/day for fluoxetine and 300 mg/day for imipramine.
If patients do not respond to or tolerate fluoxetine or
imipramine, amitriptyline is an option; alternatively, a
medication that is being partially responded to may be con-
tinued in the hope that response will improve over time.lth Questionnaire.
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sleep disturbance, anxiety or agitation, or side effects (for
example, sexual dysfunction), may be used and will be
documented.
Treatment discontinuation
Once the patient has been in remission for at least six
months, treatment will be discontinued unless the patient
has a history of multiple episodes of major depression, in
which case treatment will be maintained for two years [58].
If on treatment at end of study, treatment will be main-
tained as part of usual care. Drug supply is purchased by
the study to ensure no drug stock outs, but both medica-
tions are available free of charge to the clinics through the
Ministry of Health.
Clinical acumen model
Although psychiatric treatment is generally not currently
available in HIV clinics (nor general primary care clinics)
in Uganda, clinics that are looking to increase their
provision of depression treatment are likely to follow the
model used in many other parts of the world, which is
to train primary care providers to identify and treat
depression. Similarly, the clinical acumen model of de-
pression care relies on the discretion of primary care
providers who receive depression care training to pro-
vide depression diagnosis and treatment as deemed war-
ranted. To facilitate this process, like the protocolized
model, the clinical acumen arm also includes routine
screening of all adult clients and monthly on-site super-
vision from study psychiatrists. However, this model
relies on the clinical judgment of the primary care pro-
vider to decide whether to further evaluate and treat pa-
tients who screen positive for possible depression, as
opposed to a structured protocol (see Table 1 for an out-
line of the model and how it compares to the protoco-
lized model). Another difference between the models is
that depression care is managed entirely by nurses (with
oversight from the clinical/medical officer in charge) in
the protocolized model, whereas in the clinical acumen
model all primary care providers (who are comprised of
nurses and clinical/medical officers) are expected to pro-
vide depression care.
Training, supervision and monitoring
Training and ongoing supervision are critical for ensur-
ing quality of care and fidelity to the depression care
models, and to provide technical and emotional support
to the providers. With management of antidepressant
treatment being new to the clinic staff, the supervision is
particularly important and will help to increase the con-
fidence of the providers in their ability to provide high
quality care. Supervision is also an opportunity for the
providers to refresh and upgrade their new skills in anongoing forum that reinforces the value of the invest-
ment they have made in the training and the integration
of depression care into their HIV care practice. Further-
more, working with patients who are depressed can be
stressful and emotionally draining, so the support from
supervision can help prevent burnout and job turnover.
The training and supervision provided to the clinic staff
in both arms of the study is very similar; the only differ-
ences are that the providers in the clinical acumen arm
will not be trained to follow the parameters of a struc-
tured protocol when further assessing patients who have
screened positive for possible depression.
Start-up training
Training will start with the study’s lead investigators and
psychiatrists conducting an intensive one-day training
workshop with the clinic staff (expert clients/VHTs,
nurses, clinical/medical officers) to train them on the
structure and goals of the study, and each component of
the treatment model. One workshop will be held for the
clinics in the protocolized arm, and a separate workshop
for those in the clinical acumen arm. All nurses and
clinical/medical officers at each site will be trained so
that duties can be evenly spread, to build overall capacity
for depression care, and to mitigate against the effects of
occasional staff transfers. Training will consist of didac-
tic instruction, interactive role-playing, and small break-
out group discussions. Following the workshop, tools to
facilitate implementation of the model (laminated copies
of the PHQ-2 for the triage station, and PHQ-9/MINI
for each nurse/prescribing provider, Depression Treat-
ment Registry, psychoeducation posters and flipcharts)
will be delivered to each site, and supervising psychia-
trists will be on-site one day a week for four to six weeks
(until both the supervisor and nurse are comfortable
with the nurse’s competency in implementing the proto-
col) to provide training and mentorship (for example,
sitting in on and co-conducting assessments), after
which ongoing on-site supervision will become monthly.
Ongoing supervision
Supervision will be conducted in one-on-one sessions
between the site supervisor and each nurse (protocolized
arm) and primary care provider (clinical acumen arm),
as well as group meetings with all clinic staff involved
with implementation of depression care at the site. Fur-
thermore, the supervisor will be constantly available, day
or night, for emergency or suicide crisis consultations.
During individual supervision, the providers will present
new treatment cases since last supervision and problem-
atic or nonresponding cases, allowing the supervisor to
discuss the patient’s presenting symptoms and the treat-
ment plan for the patient, including side effect manage-
ment and dose change recommendations. Clinical notes
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the case reviews. Goals of treatment for the individual
patient will be discussed and recorded for review at sub-
sequent supervision sessions. The group meetings will
provide an opportunity for the clinic staff to work as a
team to trouble-shoot any challenges that arise, share
experiences and provide peer support to each other in
managing depressed patients, which can be emotionally
taxing as well as fulfilling.
Monitoring fidelity
Ongoing supervision and review of cases is our primary
mechanism for monitoring the fidelity of the implemen-
tation of the treatment models. At each monthly super-
vision supervisors review the charts of all patients
prescribed antidepressants within the past month, as
well as ten randomly selected charts of patients receiving
ongoing antidepressant treatment monitoring. The charts
will be reviewed for whether diagnosis, symptoms and side
effect assessment, and dosing were appropriately per-
formed, and if the patient returned for follow-up visits. Re-
sults will be aggregated and monitored on a monthly basis,
as well as used to inform the target areas for supervision.
Evaluation methods for comparing the depression care
models
To evaluate the two task-shifting models, we will compare
the implementation, effectiveness, and cost-effectiveness of
these models over a 24-month period. Using the RE-AIM
framework, we will evaluate the reach of depression
screening and treatment, adoption of depression treatment
knowledge and intervention by providers, quality of imple-
mentation (fidelity to depression care model), and effective-
ness of depression treatment on patient outcomes. As
outlined in Table 2, these implementation domains and cor-
responding outcomes will be assessed from data triangu-
lated from these data sources: (1) data abstracted from data
collection mechanisms integrated into routine care; (2)
monthly logs summarizing chart abstracted data completed
by the supervising psychiatrists; (3) survey data from a lon-
gitudinal cohort of randomly selected patients at each site
who screen positive for potential depression (PHQ-9 > 2);
and (4) survey data from longitudinal cohort of providers
involved in provision of depression care at each site. Survey
data from the patient cohort will also be used to assess how
change in depression is related to key economic and public
health outcomes. These data sources are described in more
detail below.
Primary outcomes are (1) proportion of depressed (de-
fined as PHQ-9 > 9 at baseline) patient cohort participants
who receive antidepressant treatment; and (2) depression
alleviation (reduction in PHQ-9 score). Secondary out-
comes include (1) proportion of depressed patient cohort
participants who receive further depression evaluation;(2) consistent condom use (measures with self-report); (3)
HIV treatment adherence (measured with self-report).Routine data abstraction
We will assess the implementation of screening (% of
adults screened; % screened who screen positive) by
abstracting data from the Triage Book, which the triage
station at each site uses to list the clients who attend
each day of the clinic, their vital signs, and PHQ-2 score.
PHQ-9 and MINI administration data will be recorded
in the patient’s clinic chart. Depression Treatment Regis-
try books will be installed at each site for providers to
document clients who have started antidepressant ther-
apy and their depression diagnosis, and records of each
follow-up visit that include PHQ-9 score, presence of
side effects and medication and dose prescribed.Supervision log data
From the chart reviews that the supervisors conduct
each month at each site, monthly aggregate scores are
recorded for newly prescribed patients (number with
correct diagnosis, correct prescribed antidepressant, and
correct prescribed dosage) and patients in ongoing treat-
ment (number correctly assessed for depressive symp-
toms and side effects; number correctly dosed; and
number who returned for scheduled follow-up visit in
past month).Longitudinal client cohort
Over the course of 12 months at each site, research co-
ordinators (Masters level graduates with social science
training) will recruit random samples of 150 patients
(total cohort = 1,500 patients) who the triage personnel
screen as positive for potential depression (PHQ-2 > 2),
who are confirmed to be positive in the research coordi-
nator’s own PHQ-2 administration, and who are deter-
mined to be medically stable. This sample will be
followed for 12 months with the baseline assessment ad-
ministered at the same visit in which consent is obtained
followed by assessments at Months 6 and 12. The sur-
veys will be administered by the research coordinator
using computer assisted personal interview technology,
and will include the PHQ-9 (to independently assess the
presence of depression) as well as measures of demo-
graphic and background characteristics, work activity,
clinical appointment and ART adherence, quality of life,
sexual behavior and measures of psychosocial function-
ing. All measures have been used successfully in our
prior research in Uganda and have been translated into
Luganda, the primary native language used in the study
setting. Participants will receive 10,000 Ush (approxi-
mately US$4 ) for each assessment.
Table 2 Implementation evaluation domains, outcomes measures, and data sources
RE-AIM Domain Outcome measure Sample Data source
Reach % screened with PHQ-2 All adult clinic
patients
Routine data abstraction (Triage Book)
% screened positive (PHQ-2 > 2) All adult clinic
patients
Routine data abstraction (Triage Book)
Accuracy of positive screens assessed with PHQ
survey data from patient longitudinal cohort
% positive screens who receive further
evaluation
(PHQ-9/MINI)
Patient cohort Routine data abstraction (clinic charts)
% positive screens who are depressed (PHQ-9 > 9) Patient cohort Routine data abstraction (clinic charts)
Accuracy of provider PHQ-9 assessed with
PHQ survey data
% depressed who receive antidepressants
(treatment uptake)
Patient cohort subset
(baseline PHQ-9 > 9)
Routine data abstraction
(Depression Treatment Registry)
Adoption Provider knowledge, attitudes and practices
regarding depression care
Provider cohort Provider survey data
Implementation
quality (fidelity)
Initial prescription: Appropriate diagnosis,
treatment prescription (medication and dose)
Clinic level data Supervision log data (aggregate data from monthly
chart reviews of newly prescribed patients)
Treatment management: Appropriate assessment
of symptoms, side effects, and prescription
(medication and dose)
Clinic level data Supervision log data (aggregate data from monthly
chart reviews of ongoing treatment patients)
Effectiveness Alleviation of depression Patient cohort subset
(baseline PHQ-9 > 9)
Patient PHQ-9 survey data
Improvement in condom use, work status and
ART adherence
Patient cohort subset
(baseline PHQ-9 > 9)
Patient survey data
Legend: PHQ, Patient Health Questionnaire.
Wagner et al. Trials 2014, 15:248 Page 9 of 12
http://www.trialsjournal.com/content/15/1/248Longitudinal provider cohort
A brief survey of knowledge, attitudes and practices re-
garding depression care and its influence on patients
and clinic operations will be administered to a cohort of
providers actively involved in implementing depression
care at each site. The measures will include perceived
competency in providing depression care, quality of de-
pression treatment provided, effects of the treatment
model on clinic functioning, provider burden and pa-
tient flow, and impact of depression treatment on the
patient’s quality of life. Surveys will be administered
prior to the start of implementation and then at Months 6,
12 and 24 by the research coordinators using computer-
assisted personal interview software.
Data analysis plan
Power analysis
We calculated the size of effects that our sample would
be powered to detect with regard to treatment uptake
and depression alleviation using a range of intracluster
correlation coefficient (ICC) values. Data from develop-
ing countries indicate low correlations of health out-
come variables within primary care settings, including
.03 for depression in a collaborative care trial in India
[46], and .16 for treatment process measures from astudy conducted in eight Latin American countries [59].
With 150 patients per site and assuming 30% antidepres-
sant uptake in the clinical acumen arm and ICC = .16,
we will be able to detect an increase of 28% in treatment
uptake in the protocolized arm (α = .05, 80% power; 1-
sided test). For measuring change in depression (PHQ-9)
in an intention to treat (ITT) analysis using the whole
sample, with ICC = .025, SD = 3.9 (from past research),
and 10% attrition, we will have power to detect a 1.26
difference on the PHQ-9 (α = .05, 80% power; 2-sided
test); for ICC = .01 and .05, detectable differences are .92
and 1.71. These correspond to medium effect sizes
(Cohen’s d) of .33, .40 and .49.
Statistical analysis
The analyses must account for clustering of the data,
unless the only comparisons are of cluster means or pro-
portions, using clinic as the unit of analysis. For most
outcomes we will perform such an analysis first, using
standard t-tests or, where the observations per clinic
vary, t-tests weighted by cluster-size [60]. However, rela-
tive to individual level analysis this approach is limited
by low power (low number of clusters); therefore, we
will use regression methods on individual level data for
most analyses and since the number of clusters is too
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the sensitivity of significance levels and conclusions to a
range of plausible ICC values for the outcomes,
We will use logistic regressions to compare the pro-
portion of depressed patients (according to the survey
PHQ-9) receiving depression treatment in the two arms.
The treatment uptake outcome will be estimated using
covariates to adjust for baseline characteristics such as
age, sex, and physical health. We will add interactions of
these covariates with study arm to assess which types of
patients are likely to be treated in the protocolized ver-
sus clinical acumen arms. A similar approach will be
used for other implementation outcomes such as pro-
portion of positive screens who receive further evalu-
ation with the PHQ-9. The effect of each model on
depression alleviation (change in PHQ-9) will be exam-
ined using an ITT approach and the whole sample. We
will use a repeated measures, mixed-model approach
allowing for correlation of errors over time for an indi-
vidual. The model has the following form:
Depressionit ¼ αþ β treatment modelð Þi þ γ tð Þ
þ δ treatment modelð Þi tð Þ þ θi þ εit
Where t is time period, β controls for baseline differ-
ences between the two, γ is the trend in the outcome
common to both groups, and δ is the interaction of
treatment model with time and shows the intervention
effect (protocolized model relative to the clinical acumen
model). θi is an individual random effect and εit idiosyn-
cratic period specific error. A vector of individual level
covariates Xi will be added to estimate the effects of pa-
tient characteristics and interactions of Xi and study arm
will be used to test for moderators: for example, do ef-
fects of the protocolized model vary by the patient’s
physical health at baseline? The estimates will capture
the average benefit for depressed clients, including those
who do and do not receive antidepressant treatment.
Cost-effectiveness analysis
This analysis will be performed in line with WHO CHOICE
and CHEERS (Consolidated Health Economic Evaluation
Reporting Standards) guidelines [62,63]. Using the patient
cohort data we will compare the cost-effectiveness of the
protocolized versus the clinical acumen models. Effective-
ness will be measured in terms of Quality Adjusted Life
Years (QALYs) derived from the Medical Outcomes Study-
HIV (MOS-HIV) Study survey measures [64], calculated
over all depressed clients, treated or not. Differences in
effectiveness across the two arms will be driven in part by
differences in the efficacy of treatment and depression alle-
viation. Sensitivity analyses will consider impacts on cost-
effectiveness of variations in % screened, and % who receive
diagnostic evaluation, as well as variation in cost andefficacy parameters. We will compute resource use and
costs in international dollars using a societal perspective
(that is including patient, clinic and Ministry of Health pub-
lic costs). We will obtain overhead and annualized capital
costs from the WHO-CHOICE database for Uganda; costs
for drugs and human resources will be estimated from the
Mildmay financial records and Uganda Public Service salary
structure data.Discussion
With growing evidence of the damaging effects of de-
pression on HIV prevention and care, and the relative
absence of depression treatment in HIV care programs
throughout SSA despite its high prevalence, INDEPTH-
Uganda aims to identify an approach to integrating de-
pression treatment into HIV care that is both effective
and sustainable in resource constrained settings. With
the severe shortage of psychiatric specialists in Uganda
and SSA, and limited numbers of physicians to care for
ever-growing numbers of PLWHIV in care, task-shifting
models are essential, but establishing feasibility, efficacy
and cost-effectiveness are critical for widespread imple-
mentation. Task-shifting, protocolized approaches to
overcoming shortages of highly trained mental health
professionals in the provision of depression treatment
have been shown to be effective in resource-constrained
settings and the US [41-51], but this may be the first
study of such a model with PLWHIV, and in SSA. With
active engagement and collaboration with key commu-
nity stakeholders, policy makers and the clinic staff in-
volved in implementation, we have sought to adapt a
nurse-driven, protocolized model of depression care that
is resource-efficient and not overly burdensome for
already busy clinics, with the goal of being sustainable in
the long term. If we demonstrate that this task-shifting,
protocolized approach to depression treatment is feas-
ible and cost-effective, it will establish a model that ad-
dresses the human resource challenges to building the
capacity for sustainable depression treatment. Findings
may have implications not only for PLWHIV in SSA,
but also other developing regions, non-HIV populations,
and possibly treatment of other diseases.Trial status
The trial is actively enrolling participants.
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